

DIABETES 2019

28th International Conference on

Diabetes and Endocrinology &

3rd International Conference on

Diabetes and Metabolism

November 29-30, 2019 | Frankfurt, Germany

Retrospective real-life efficacy assessment of teneligliptin in Indian T2DM patients

Nikhil S Nasikkar

K J Somiaya Medical College, India

Background: Teneligliptin is been introduced recently in Indian market and data available are limited on Indian patients. Hence, the hospital based real life retrospective evaluation was planned out to evaluate, the efficacy of teneligliptin in type 2 diabetes mellitus in Indian population. Hence study was designed, a retrospective evaluation, of efficacy of teneligliptin in type 2 diabetes mellitus in Indian population.

Methods: Data of 11400 patients, who were prescribed teneligliptin was collected from hospital records. Teneligliptin 20mg was prescribed to all patients who were uncontrolled on other OHAs and for a mean duration of 8 weeks. Parameter evaluated in this study were change in FBG, PPBG and HbA1c from the baseline at 8week. With profile of outcome i.e. response and failure rates were also assessed with respect to age, gender, BMI and duration of diabetes.

Results: Of 11400 patients were enrolled, 6612 were males and 4788 females. The average age was 52.77 years among the study population. The mean duration of diabetes was 23 months. There was significant change in HbA1c, fasting and postprandial blood glucose levels at 2.55 ±1.88 months (p=0.001) of teneligliptin therapy. Changes in HbA1c, FPG and PPG from baseline to end of study were-1.35±1.08%

(p=0.001), -49.01±26.48 mg/dl (p=0.001) and -79.80±32.10 mg/dl (p=0.001) respectively. Out of 11400 patients, 1642 (14.4%) were non-responders where it was further sub analysed with different parameter such as age, gender, BMI and duration of diabetes in order to observe response of teneligliptin in diabetic patients.

Conclusions: This real life retrospective evaluation showed efficacy of teneligliptin in real world scenario. It can be an effective alternative to conventional gliptins available for prescription in India.

Speaker Biography

Nikhil Sunil Nasikkar is a postgraduate in internal medicine from national board of examinations, From Bhabha Atomic research centre hospital MUMBAI. Also a postgraduate in diebetilogy from Annamalai University Tamilinadu.India. Has experience of diabetes management since last 16 years both inpatient and outpatient . Has publications both national and international level. Practising as consultant diabetics specialist and physician in Mumbai. Also working as. Assistant professor in department of medicine and run the depart of diabetes and endocrine. Currently working on diabetes and pregnancy with use of flash glucometers. Active member or RSSDI national body for diabetes research in India. Organising co secretary 48 th National RSSDI conference in Mumbai Dec 2020.

e: drniknash@gmail.com

